CA
TGTX icon

Crewe Advisors’s TG Therapeutics TGTX Stock Holding History

Crewe Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.3K Buy
460
+223
+94% +$9.13K ﹤0.01% 558
2026
Q1 		$7.87K Buy
237
+196
+478% +$5.84K ﹤0.01% 693
2025
Q4 		$1.22K Buy
+41
New +$1.34K ﹤0.01% 961

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Crewe Advisors's TGTX Position: Q2 2026 in Review

Crewe Advisors increased its TG Therapeutics (TGTX) stake by 94% in Q2 2026, buying an estimated $9.13K and bringing the position to 460 shares worth $25.3K. The position accounts for ﹤0.01% of the portfolio, ranked #558.

Crewe Advisors first reported a position in TGTX in Q4 2025 and has held it in 3 quarters since. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Crewe Advisors held 460 shares of TG Therapeutics worth $25.3K as of Q2 2026.
  • Crewe Advisors bought 223 TG Therapeutics shares in Q2 2026, an estimated $9.13K.
  • TG Therapeutics made up ﹤0.01% of Crewe Advisors's portfolio in Q2 2026, its #558 holding.
  • Crewe Advisors first reported a position in TG Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Crewe Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.